Literature DB >> 18940885

The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre.

Fu-de Zhou1, Ming-hui Zhao, Wan-zhong Zou, Gang Liu, Haiyan Wang.   

Abstract

BACKGROUND: Primary glomerular disease (PGD) is the leading cause of end-stage renal disease (ESRD) in China. With the development of socioeconomic status of Chinese people in the last two decades, PGD in ESRD is intent to decrease. However, whether this affects the spectrum of PGD is not clear. The aim of the current study is to investigate the changing spectrum of PGD in China.
METHODS: The records of 5398 consecutive native renal biopsies performed in adults (>or=14 years of age) in our centre between 1993 and 2007 were retrospectively analysed. The criteria for renal biopsy and pathologic diagnosis were kept unchanged. The patients were grouped according to a 5-year interval, 1993-97 (period 1), 1998-2002 (period 2) and 2003-07 (period 3). Then they were divided into four groups according to age for stratified analysis: 14-24 years, 25-44 years, 45-59 years and the elderly (>or=60 years).
RESULTS: Three thousand, three hundred and thirty-one patients were diagnosed with PGD. PGD remained the most common renal disease, accounting for 65.9%, 57.7% and 63.2% in period 1, 2 and 3, respectively, without any significant difference. The proportion of elder patients increased significantly from 0% in 1993 to 9.1% in 2007 (P < 0.001). Within 1993-97, the leading PGD was IgA nephropathy (50.7%), followed by non-IgA MsPGN (19.9%), membranous nephropathy (MN) (13.3%) and minimal change disease (MCD) (6.3%), while within 2003-07, the most common PGD was still IgAN (58.2%), but followed by MN (14.3%), MCD (13.4%) and non-IgA MsPGN (7.0%). The age-adjusted frequency of IgAN and MCD increased significantly from period 1 to period 3 (P < 0.01 and P < 0.001, respectively), while that of non-IgA MsPGN, EnPGN and MPGN decreased significantly (P < 0.001, P < 0.01 and P < 0.05, respectively). There was no significant change in the age-adjusted frequency of FSGS, MN and CreGN during the study period. However, when patients were stratified by age, a sixfold increase in frequency of FSGS was identified in the 14- to 24-year group (P < 0.01).
CONCLUSIONS: The spectrum of primary glomerulonephritis has changed within the last 15 years. The relative frequency of non-IgA MsPGN, EnPGN and MPGN decreased significantly, while that of MCD and IgA nephropathy increased significantly. The relative frequency of FSGS increased significantly in younger patients.

Entities:  

Mesh:

Year:  2008        PMID: 18940885     DOI: 10.1093/ndt/gfn554

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  59 in total

1.  Growth-dependent podocyte failure causes glomerulosclerosis.

Authors:  Akihiro Fukuda; Mahboob A Chowdhury; Madhusudan P Venkatareddy; Su Q Wang; Ryuzoh Nishizono; Tsukasa Suzuki; Larysa T Wickman; Jocelyn E Wiggins; Timothy Muchayi; Diane Fingar; Kerby A Shedden; Ken Inoki; Roger C Wiggins
Journal:  J Am Soc Nephrol       Date:  2012-07-05       Impact factor: 10.121

2.  Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.

Authors:  Xia-Hong Shen; Shao-Shan Liang; Hui-Mei Chen; Wei-Bo Le; Song Jiang; Cai-Hong Zeng; Min-Lin Zhou; Hai-Tao Zhang; Zhi-Hong Liu
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

3.  Genome-Wide Meta-Analysis Identifies Three Novel Susceptibility Loci and Reveals Ethnic Heterogeneity of Genetic Susceptibility for IgA Nephropathy.

Authors:  Ming Li; Ling Wang; Dian-Chun Shi; Jia-Nee Foo; Zhong Zhong; Chiea-Chuen Khor; Chiara Lanzani; Lorena Citterio; Erika Salvi; Pei-Ran Yin; Jin-Xin Bei; Li Wang; Yun-Hua Liao; Jian Chen; Qin-Kai Chen; Gang Xu; Geng-Ru Jiang; Jian-Xin Wan; Meng-Hua Chen; Nan Chen; Hong Zhang; Yi-Xin Zeng; Zhi-Hong Liu; Jian-Jun Liu; Xue-Qing Yu
Journal:  J Am Soc Nephrol       Date:  2020-09-10       Impact factor: 10.121

4.  Efficacy and safety of glucocorticoids for patients with IgA nephropathy: a meta-analysis.

Authors:  Ge Qian; Xiaoyu Zhang; Weicheng Xu; Hequn Zou; Yongqiang Li
Journal:  Int Urol Nephrol       Date:  2019-03-06       Impact factor: 2.370

Review 5.  Inflammation in IgA nephropathy.

Authors:  Thomas Rauen; Jürgen Floege
Journal:  Pediatr Nephrol       Date:  2017-03-14       Impact factor: 3.714

6.  Native kidney biopsies in Armenian and Swiss children: high prevalence of amyloidosis in Yerevan and of IgA nephropathy in Zurich.

Authors:  Guido F Laube; Ashot Sarkissian; Helen Nazaryan; Giuseppina Spartà; Armen Sanamyan; Ara Babloyan; Ernst Leumann; Ariana Gaspert
Journal:  Virchows Arch       Date:  2014-11-08       Impact factor: 4.064

7.  Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015.

Authors:  Naoki Nakagawa; Naoyuki Hasebe; Motoshi Hattori; Michio Nagata; Hitoshi Yokoyama; Hiroshi Sato; Hitoshi Sugiyama; Akira Shimizu; Yoshitaka Isaka; Shoichi Maruyama; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2017-12-06       Impact factor: 2.801

8.  FSGS as an Adaptive Response to Growth-Induced Podocyte Stress.

Authors:  Ryuzoh Nishizono; Masao Kikuchi; Su Q Wang; Mahboob Chowdhury; Viji Nair; John Hartman; Akihiro Fukuda; Larysa Wickman; Jeffrey B Hodgin; Markus Bitzer; Abhijit Naik; Jocelyn Wiggins; Matthias Kretzler; Roger C Wiggins
Journal:  J Am Soc Nephrol       Date:  2017-07-18       Impact factor: 10.121

9.  Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China.

Authors:  Xin Xu; Guobao Wang; Nan Chen; Tao Lu; Sheng Nie; Gang Xu; Ping Zhang; Yang Luo; Yongping Wang; Xiaobin Wang; Joel Schwartz; Jian Geng; Fan Fan Hou
Journal:  J Am Soc Nephrol       Date:  2016-06-30       Impact factor: 10.121

Review 10.  Nephrology in china.

Authors:  Zhi-Hong Liu
Journal:  Nat Rev Nephrol       Date:  2013-07-23       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.